NDAINTRAVENOUSSOLUTION
Approved
Jan 2017
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
CORPHEDRA (ephedrine sulfate) by Pfizer is α- and ß adrenergic receptors and indirectly causes the release of norepinephrine from sympathetic neurons. First approved in 2017.
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CORPHEDRA is an intravenous ephedrine sulfate solution approved in 2017 for management of hypotension, primarily in perioperative and critical care settings. It works through dual α- and β-adrenergic receptor activation and indirect norepinephrine release from sympathetic neurons, increasing arterial pressure, cardiac output, and peripheral resistance. The product is currently at peak commercial lifecycle under Pfizer sponsorship.
Peak
IV acute care product at peak lifecycle indicates stable, mature commercial operations with focus on hospital channel penetration and prescriber loyalty.
Mechanism of Action
α- and ß adrenergic receptors and indirectly causes the release of norepinephrine from sympathetic neurons. Pressor effects by direct alpha- and beta-adrenergic receptor activation are mediated by increases in arterial pressures, cardiac output, and peripheral resistance. Indirect adrenergic…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Bioequivalence Study of Desloratadine and Pseudoephedrine Sulfate Extended-release Tablets Under Fasting Conditions
Started Apr 2006
34 enrolled
Healthy
Career Relevance
CORPHEDRA offers career opportunities in hospital-focused commercial and medical affairs roles, particularly for professionals with critical care or acute care expertise. The peak lifecycle and zero linked job count suggest this is a stable, mature product with selective hiring focused on specialized hospital and clinical roles rather than broad expansion.
Hospital Account Manager
Worked on CORPHEDRA at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.